NCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
Clinical Trials
24 trialsNCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT04659603 2025-10-01
CARMEN-BT01
Sanofi
Phase 2 Terminated
NCT06876636 2025-07-29
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Xijing Hospital
Phase NA Active not recruiting
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
NCT06611891 2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3 Recruiting
NCT06857305 2025-03-04
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Enrolling by invitation
NCT06718933 2025-02-06
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Fudan University
Phase 1/2 Recruiting
NCT05420779 2024-05-08
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Tasly Pharmaceutical Group Co., Ltd
Phase 2 Recruiting
NCT06298084 2024-03-29
ICARUSBREAST02
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT03322215 2024-03-08
PASIPHAE
Karolinska University Hospital
Phase 2 Terminated
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT04262804 2023-08-22
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
Phase 2 Unknown
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT04556292 2020-09-21
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 2 Unknown
NCT01876251 2019-03-15
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Pfizer
Phase 1 Terminated
NCT02664103 2018-02-01
METRO-ABC
Sanofi
Phase 2 Completed
NCT03086785 2018-01-17
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Unknown